New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
09:09 EDTMNK, FLXN, INSYBMO Capital specialty pharma analyst holds analyst/industry conference call
Specialty Pharmaceuticals Analyst Maris, along with President & CEO Nathaniel Katz, MD of Analgesic Solutions, discuss whether the FDA is looking for alternatives to complement the opioid pain relief medications on the market, including Mallinckrodt’s Xartemis and MNK-155, Flexion’s FX005 and Insys’s Subsys on an Analyst/Industry conference call to be held on May 23 at 10 am.
News For MNK;FLXN;INSY From The Last 14 Days
Check below for free stories on MNK;FLXN;INSY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
09:03 EDTMNKMallinckrodt to present data on MNK-155, XARTEMIS XR at PAINWeek
Subscribe for More Information
August 25, 2014
10:40 EDTMNKBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
09:11 EDTINSYOn The Fly: Pre-market Movers
Subscribe for More Information
07:07 EDTINSYInsys Therapeutics receives FDA orphan drug designation for CBD
Insys Therapeutics announced that the FDA has granted orphan drug designation to its pharmaceutical cannabidiol, or CBD, for the treatment of glioblastoma multiforme, or GBM, the most common and most aggressive malignant primary brain tumor in humans. In addition to receiving orphan drug designation, Insys has recently entered into an exclusive licensing agreement with California Pacific Medical Center on behalf of its Research Institute, or CPMCRI, based in San Francisco to license CPMCRI's patent rights related to the usage of cannabinoids for the treatment of GBM.
August 22, 2014
09:02 EDTMNKMallinckrodt names Furey Chief Compliance Officer
Subscribe for More Information
August 21, 2014
15:16 EDTMNKDEA restricts painkiller drug prescriptions to curb abuse, WSJ reports
The Drug Enforcement Agency, or DEA, will reclassify hydrocodone combination painkiller drugs and place them in the category of medical substances that have the highest potential for harm in an attempt to curb the widespread abuse of the drugs, according to The Wall Street Journal. The rescheduling of the drugs will take effect in 45 days and result in people being able to obtain the drug for only 90 days without obtaining a new prescription. Major manufacturers of these drugs include Teva Pharmaceutical (TEVA), Mallinckrodt (MNK), AbbVie (ABBV), and Actavis (ACT). Reference Link
August 19, 2014
09:21 EDTMNKMallinckrodt now a component of the S&P 500 Index
The inclusion comes following the completion of Mallinckrodt’s acquisition of Questcor Pharmaceuticals last week. In addition to increasing the market capitalization of Mallinckrodt, the combination has significantly strengthened the company’s balance sheet, cash generation and leverage position.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use